Advertisement
Advertisement
U.S. Markets open in 3 hrs 42 mins
Advertisement
Advertisement
Advertisement
Advertisement

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
188.77+7.81 (+4.32%)
At close: 04:00PM EDT
188.77 0.00 (0.00%)
After hours: 04:53PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close180.96
Open184.52
Bid0.00 x 1200
Ask0.00 x 800
Day's Range180.98 - 190.16
52 Week Range137.21 - 306.98
Volume446,625
Avg. Volume520,904
Market Cap10.437B
Beta (5Y Monthly)0.95
PE Ratio (TTM)170.06
EPS (TTM)1.11
Earnings DateOct 26, 2022 - Oct 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est236.89
  • Benzinga

    Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact

    Repligen Corporation (NASDAQ: RGEN) entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo and the development of future products and technologies in partnership with DRS Daylight Solutions. Also read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says. Both companies

  • GlobeNewswire

    Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement

    Signs 15-year Strategic Collaboration and Exclusive License AgreementWALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Through this agreement, Repligen will assume responsibility for the c

  • Zacks

    Repligen (RGEN) is a Top-Ranked Growth Stock: Should You Buy?

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Advertisement
Advertisement